No profile data available.
INmune Bio, Inc. (INMB) is a healthcare company in the biological analysis equipment industry, based in Boca Raton, United States, with about 21 full-time employees.
It reported revenue of $50,000 for fiscal year 2025, up 257.1% from fiscal year 2024, and net income of -$45.93 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $52.45 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
INmune Bio reported $50,000 in revenue for fiscal year 2025, up 257.1% from $14,000 in fiscal year 2024. In Q1 2026 revenue was $0.
$52.45 million as of October 9, 2026.
Listed companies of a similar size in the same industry (biological analysis equipment) include Quanterix Corporation (QTRX), MaxCyte, Inc. (MXCT), Seer, Inc. (SEER), Rapid Micro Biosystems, Inc. (RPID).